Tighe Reardon

Insider Reports History

Reporting-owner location: La Jolla, CA
Latest reporting-owner signature: /s/ Tighe Reardon
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Tighe Reardon

Form 4 holding Acting Chief Financial Officer

Janux Therapeutics, Inc.

Security class: Common Stock
Shares / value: 3,340,018
Estimated value: $182,865,986
Report date: 03 Jun 2024
Price: $54.75
Ownership: By Avalon BioVentures SPV I, L.P.

Form 4 holding Acting Chief Financial Officer

Janux Therapeutics, Inc.

Security class: Common Stock
Shares / value: 633,673
Estimated value: $34,693,597
Report date: 03 Jun 2024
Price: $54.75
Ownership: By Avalon BioVentures I, LP

Form 4 holding Acting Chief Financial Officer

Janux Therapeutics, Inc.

Security class: Common Stock
Shares / value: 174,989
Estimated value: $9,580,648
Report date: 03 Jun 2024
Price: $54.75
Ownership: Direct

Form 4 holding Acting Chief Financial Officer

Janux Therapeutics, Inc.

Security class: Stock Option (right to buy)
Shares / value: 157,000
Estimated value
Report date: 02 Jan 2024
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Tighe Reardon

4 JANX

Janux Therapeutics, Inc.

Report period: 03 Jun 2024
Transactions: 2
Transaction value: -$45,043,975
Accepted by SEC: 05 Jun 2024, 19:23
Role: Acting Chief Financial Officer
Next action: Open filing details

4 JANX

Janux Therapeutics, Inc.

Report period: 02 Jan 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 03 Jan 2024, 16:52
Role: Acting Chief Financial Officer, 10%+ Owner
Next action: Open filing details

4 JANX

Janux Therapeutics, Inc.

Report period: 13 Nov 2023
Transactions: 1
Transaction value: +$4,988,643
Accepted by SEC: 15 Nov 2023, 16:48
Role: Acting Chief Financial Officer, 10%+ Owner
Next action: Open filing details

4 JANX

Janux Therapeutics, Inc.

Report period: 03 Jan 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 05 Jan 2023, 15:34
Role: Acting Chief Financial Officer, 10%+ Owner
Next action: Open filing details

4 JANX

Janux Therapeutics, Inc.

Report period: 03 Jan 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 05 Jan 2022, 16:27
Role: Acting Chief Financial Officer, 10%+ Owner
Next action: Open filing details

4 JANX

Janux Therapeutics, Inc.

Report period: 15 Jun 2021
Transactions: 5
Transaction value: +$10,699,987
Accepted by SEC: 16 Jun 2021, 18:11
Role: Acting Chief Financial Officer, 10%+ Owner
Next action: Open filing details

3 JANX

Janux Therapeutics, Inc.

Report period: 10 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 10 Jun 2021, 19:18
Role: Acting Chief Financial Officer, 10%+ Owner
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .